KDM4A Antibody

Code CSB-PA012137LA01HU
Size US$166
Order now
Image
  • Immunohistochemistry of paraffin-embedded human testis tissue using CSB-PA012137LA01HU at dilution of 1:100

  • Immunohistochemistry of paraffin-embedded human brain tissue using CSB-PA012137LA01HU at dilution of 1:100

  • Immunofluorescent analysis of MCF-7 cells using CSB-PA012137LA01HU at dilution of 1:100 and Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L)

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) KDM4A Polyclonal antibody
Uniprot No.
Target Names
KDM4A
Alternative Names
JHDM3A antibody; JmjC domain containing histone demethylation protein 3A antibody; JmjC domain-containing histone demethylation protein 3A antibody; JMJD2 antibody; JMJD2A antibody; jumonji C domain containing histone demethylase 3A antibody; Jumonji domain containing 2 antibody; Jumonji domain containing 2A antibody; Jumonji domain containing protein 2A antibody; Jumonji domain-containing protein 2A antibody; KDM4A antibody; KDM4A_HUMAN antibody; KIAA0677 antibody; Lysine (K) specific demethylase 4A antibody; Lysine-specific demethylase 4A antibody; TDRD14A antibody; Tudor domain containing 14A antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Lysine-specific demethylase 4A protein (127-364AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The KDM4A Antibody (Product code: CSB-PA012137LA01HU) is Non-conjugated. For KDM4A Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA012137LB01HU KDM4A Antibody, HRP conjugated ELISA
FITC CSB-PA012137LC01HU KDM4A Antibody, FITC conjugated
Biotin CSB-PA012137LD01HU KDM4A Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form
Liquid
Tested Applications
ELISA, IHC, IF
Recommended Dilution
Application Recommended Dilution
IHC 1:20-1:200
IF 1:50-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Histone demethylase that specifically demethylates 'Lys-9' and 'Lys-36' residues of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-4', H3 'Lys-27' nor H4 'Lys-20'. Demethylates trimethylated H3 'Lys-9' and H3 'Lys-36' residue, while it has no activity on mono- and dimethylated residues. Demethylation of Lys residue generates formaldehyde and succinate. Participates in transcriptional repression of ASCL2 and E2F-responsive promoters via the recruitment of histone deacetylases and NCOR1, respectively.; Crucial for muscle differentiation, promotes transcriptional activation of the Myog gene by directing the removal of repressive chromatin marks at its promoter. Lacks the N-terminal demethylase domain.
Gene References into Functions
  1. MiR150 plays an important role in the development of lung cancer by serving as an oncogene via the SIRT2/JMJD2A signaling pathway. PMID: 29901178
  2. Data show that lysine demethylase 4 A/B double tudor domains (KDM4A/B DTDs) bind strongly to histone H3 (H3)K23me3. PMID: 27841353
  3. Generation of 2-hydroxyglutarate by mutated IDH1/2 leads to the activation of mTOR by inhibiting KDM4A. PMID: 27624942
  4. The present study indicates a novel evidence for JMJD2A in tumorigenesis by upregulating miR372 in liver cancer cells. PMID: 28467776
  5. JMJD2A regulated aerobic glycolysis by regulating LDHA expression. Therefore, the novel JMJD2A-LDHA signaling pathway could contribute to the Warburg effects in NPC progression. PMID: 28693517
  6. Findings inidicate a unique breast cancer stem-like cells (BCSC) culture system for drug screening and offer preclinical proof of concept for lysine demethylase 4A (KDM4A) inhibition as a new strategy to treat triple-negative breast cancer. PMID: 28883001
  7. The pyruvate dehydrogenase kinases (PDKs) PDK1 and PDK3 are direct targets of KDM4A and E2F1 and modulate the switch between glycolytic metabolism and mitochondrial oxidation. PMID: 27626669
  8. results suggest that KDM4A possesses the potential to act as an oxygen sensor in the context of chromatin modifications, with possible implications for epigenetic regulation in hypoxic disease states PMID: 28051298
  9. Here we show that JMJD2A, the first identified Jumonji C domain-containing histone demethylase, is the histone demethylase responsible for SUMO-2/3 enrichment on the Kaposi's sarcoma associated herpesvirus genome during viral reactivation PMID: 28212444
  10. Lgr4 activates Jmjd2a/AR signaling pathway to promote interaction AR with PSA promoter, causing reduction of prostate cancer apoptosis and cell cycle arrest. PMID: 27743893
  11. We demonstrate the previously unreported inhibitory action of PKF118-310 on KDM4A. Our findings open up the possibility of developing the first KDM4A-specific inhibitors and derivatives. PMID: 27767379
  12. KDM4A downregulation promotes autophagy in glioma cell lines. PMID: 27514525
  13. ERG promotes prostate tumorigenesis together with KDM4A through the upregulation of YAP1. A corollary is that KDM4A as well as YAP1 inhibitors may prove beneficial for the therapy of ERG-overexpressing prostate tumors. PMID: 27109047
  14. In pancreatic neoplasms, miR-137 targets KDM4A mRNA during Ras-induced senescence and activates both p53 and retinoblastoma (pRb) tumor suppressor pathways. PMID: 26904954
  15. Study demonstrates that JMJD2A contributes to tumorigenesis in non-small cell lung cancer (NSCLC) by regulating miR-150. Additionally, JMJD2A overexpression is associated with a poor prognosis for NSCLC patients. PMID: 26498874
  16. High KDM4A expression is associated with endometrial cancer progression. PMID: 26397136
  17. Studies indicate that histone lysine demethylase (JmjC-KDM) KDM4A protein has been implicated in numerous cancers and cardiovascular diseases. PMID: 25832587
  18. KDM4A is regulated by hsa-mir-23a-3p, hsa-mir-23b-3p, and hsa-mir-137. PMID: 26755726
  19. these data reveal a JMJD2A/ETV1/YAP1 axis that promotes prostate cancer initiation and that may be a suitable target for therapeutic inhibition. PMID: 26731476
  20. Results indicate that SCF(Fbxo22)-KDM4A is an E3 ubiquitin ligase that targets methylated p53 and regulates key senescent processes. PMID: 26868148
  21. This study showed that KDM4A interacts with RNA Polymerase I, associates with active ribosomal RNA genes and is required for serum-induced activation of rDNA transcription. PMID: 26729372
  22. Jra recruits the HP1a/KDM4A complex to its gene body region upon osmotic stress to reduce H3K36 methylation levels and disrupt H3K36 methylation-dependent histone deacetylation PMID: 25945750
  23. A coding single-nucleotide polymorphism in lysine demethylase KDM4A associates with increased sensitivity to mTOR inhibitors PMID: 25564517
  24. KDM4 mediates nutrient-limitation signaling that leads to the transcriptional induction of autophagy. PMID: 25660547
  25. this review focuses on describing the structure, mechanisms, and function of KDM4A and primarily discusses the role of KDM4A in cancer development and the importance of KDM4A as a potential therapeutic target. [review] PMID: 25633974
  26. Negative regulation of Sp1 by JMJD2A causes downregulation of Sp1 in highly invasive breast cancer cells. PMID: 25193278
  27. The data indicate that JMJD2A could promote breast cancer progression through transcriptional repression of the tumor suppressor ARHI. PMID: 24886710
  28. JMJD2A is a promoter of endometrial carcinoma cell proliferation and survival, and is a potential novel drug target. PMID: 24815446
  29. Those findings demonstrate that JMJD2A regulates gastric cancer growth and serves as an independent prognostic factor, and implicate that JMJD2A may be a promising target for intervention. PMID: 24802408
  30. Findings demonstrate that KDM4A overexpression results in site-specific copy gain of regions amplified in human tumors. PMID: 23871696
  31. analysis of the nickel-induced inhibition of truncated constructs of JMJD2A and JMJD2C histone demethylases using X-ray absorption spectroscopy PMID: 23692052
  32. JMJD2A regulation has a role in human carcinogenesis through regulation of the G(1)/S transition PMID: 23603248
  33. The expression of JMJD2A inhibits Ras-mediated CHD5 induction leading to a reduced activity of the p53 pathway. PMID: 23168260
  34. overexpression of JMJD2A may contribute to breast tumor formation by stimulating ERalpha activity and that JMJD2A may be a breast-relevant oncoprotein. PMID: 22948256
  35. data indicate that JMJD2A is a novel promoter of colon cancer cell proliferation and survival, which mediates its effects in p53-dependent and -independent ways PMID: 22134899
  36. JMJD2A gene could result in cell cycle change and proliferation inhibition, and lead to suppress tumor cell invasion and migration. PMID: 21962223
  37. JMJD2A and AR levels were significantly lower in malignant versus benign urothelium, while increased LSD1 levels were observed in malignant urothelium relative to benign; a significant reduction in all three proteins occurred with cancer stage progression PMID: 21400613
  38. SKP1-Cul1-F-box and leucine-rich repeat protein 4 (SCF-FbxL4) ubiquitin ligase regulates lysine demethylase 4A (KDM4A)/Jumonji domain-containing 2A (JMJD2A) protein PMID: 21757720
  39. these results demonstrate that SCF(FBXO22) regulates changes in histone H3 marks and cognate transcriptional control pathways by controlling KDM4A levels PMID: 21768309
  40. The expression of JMJD2A was upregulated in human hypertrophic cardiomyopathy patients. PMID: 21555854
  41. The authors show that knockdown of JMJD2A, an H3K9me3 demethylase, attenuates viral titers, whereas its overexpression increases Kaposi's sarcoma-associated herpesvirus reactivation. PMID: 21228229
  42. JHDM3A(GFP)(701) is a suitable catalytic module that can be targeted, under the control of a guide protein, to specific loci where the chromatin H3K9me3 status and the milieu of gene expression are to be modified. PMID: 21148561
  43. The ability of JMJD2A to associate with retinoblastoma proteins and histone deacetylase 1 implies an important role for this protein in cell proliferation and oncogenesis. PMID: 15927959
  44. JMJD2A selectively represses the expression of the achaete scute-like homologue 2 (ASCL2) gene but not other imprinted genes in the same imprinted locus in HeLa cells PMID: 16024779
  45. crystal structure of the double tudor domain of JMJD2A both in the presence and absence of a trimethylated H3-K4 peptide PMID: 16601153
  46. JHDM3A may function in euchromatin to remove histone methylation marks that are associated with active transcription PMID: 16732292
  47. identified two related histone demethylases, JMJD2A and JMJD2D PMID: 17555712
  48. how human JMJD2A, which is selective towards tri- and dimethylated histone H3 lysyl residues 9 and 36 (H3K9me3/me2 and H3K36me3/me2), discriminates between methylation states and achieves sequence selectivity for H3K9 PMID: 17589501
  49. Crystal structures of the JMJD2A catalytic domain in complex with H3K9me3, H3K36me2 and H3K36me3 peptides are presented. PMID: 17589523
  50. Human JMJD2A was expressed in undifferentiated and differentiated ES cells. PMID: 17611647

Show More

Hide All

Subcellular Location
Nucleus.
Protein Families
JHDM3 histone demethylase family
Tissue Specificity
Ubiquitous.
Database Links

HGNC: 22978

OMIM: 609764

KEGG: hsa:9682

STRING: 9606.ENSP00000361473

UniGene: Hs.155983

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*